Abstract
BRAF V600E is a disease defining mutation for hairy cell leukemia (HCL), which helps in its diagnosis and differentiation from morphologically similar splenic marginal zone lymphoma (SMZL) and HCL-variant (HCL-v). Forty eight cases:HCL(n = 34), SMZL(n = 11) and HCL-v(n = 3) were included. Of these, 32 were retrospective and 16 were prospective. DNA was extracted, in retrospective cases from cells obtained by smears from bone marrow aspirate/trephine imprint (BMA/BMTx) slides, and in prospective cases from peripheral blood (PB)/BMA samples. BRAF V600E mutation testing was done using ARMS-PCR. BRAF V600E mutation was positive in all HCL and negative in all SMZL and HCL-v cases. DNA extracted from BMA/BMTx slides gave results comparable to DNA extracted from PB/BMA samples. Median age of presentation for HCL (53 years) and SMZL (56 years) were quite similar, however, HCL-v (71 years) cases presented at an older age. Statistically significant differences between the three groups were seen for total leucocyte, platelet, absolute lymphocyte and monocyte counts, bone marrow-infiltration pattern, reticulin fibrosis, and an expression of CD11c, CD25, CD103, CD123, and CD200. The use of BMA/BMTx smears for DNA extraction was found to be a useful alternative to DNA extraction from formalin-fixed paraffin-embedded biopsy sections. ARMS-PCR is an efficient and specific technique to detect BRAF V600E mutation in HCL patients.
Similar content being viewed by others
References
Foucar K, Falini B, Stein H (2017) Hairy cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon, IARC, pp 226–228
Sharpe RW, Bethel KJ (2006) Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am 20:1023–1049
Bethel KJ, Sharpe RW (2003) Pathology of hairy cell leukaemia. Best Pract Res Clin Haematol 16:15–31
Matutes E (2006) Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin N Am 20:1051–1063
Shao H, Calvo KR, Gronborg M, Tembhare PR, Kreitman RJ, Steller-Stevenson M et al (2013) Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 37:401–409
Gidron A, Tallman MS (2005) Hairy cell leukemia: towards a curative strategy. Hematol Oncol Clin N Am 20:1153–1162
Else M, Ruchlemer R, Osuji N et al (2005) Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 104:2442–2448
Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305–2315
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867
Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A et al (2012) Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119(1):192–195
Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O’Brien S et al (2012) Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol 138(1):153–156
Chen D, Wang YY, Chuai ZR, Huang JF, Wang YX, Liu K et al (2014) High-Resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis. Sci Rep 4:4168
Carbonell P, Turpin MC, Torres-Moreno D, Molina-Martinez I, García-Solano J, Perez-Guillermo M et al (2011) Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. J Mol Diagn 13(5):467–473
Caper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122(1):11–19
Foucar K, Falini B, Stein H (2017) Hairy cell leukaemia. In: Swerdlow SH, Campo E, Harris NL, et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 226–228
Piris M, BMA, Issacson PG, Swerldow PG, et al (2017) Splenic marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC, pp 223–225
Piris MA, PittalugaFoucar K, Mollejo M, et al (2017) Hairy cell leukaemia variant. In: Swerdlow SH, Campo E, Harris NL, et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 230–231
Huang T, Zhuge J, Zhang WW (2013) Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR. Biomark Res 1:3
World Health Organization (2001) Dept. of Nutrition for Health and Development. Iron deficiency anaemia : assessment, prevention and control : a guide for programme managers. World Health Organization, Geneva
Bates I, Lewis SM (2011) Reference ranges and normal values. In: Bain BJ, Bates I, Laffan MA, Lewis SM (eds) Practical haematology, 11th edn. Churchill Livingstone, Philadelphia, pp 11–22
Stasi R (2012) How to approach thrombocytopenia. Hematol Am Soc Hematol Educ Program 2012:191–197
Grever MR (2010) How I treat hairy cell leukemia. Blood 115:21–28
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly J et al (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129:553–560
Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119:188–191
Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S et al (2012) Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 97:780–783
Samuel J, Macip S, Dyer MJS (2014) Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 370:286–288
Tiacci E, Park JH, Carolis LD, Chung SS, Broccoli A, Scott S et al (2015) Targeting mutant BRAF in relapsed or refractory Hairy-Cell Leukemia. N Engl J Med 373:1733–1747
Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M et al (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 119:3330–3332
Thomas C, Amanuel B, Finlayson J, Grieu- Iacopetta F, Spagnolo DV, Erber WN (2015) BRAF mutation detection in hairy cell leukaemia from archival haematolymphoid specimens. Pathology 47:349–354
Dores GM, Matsuno RK, Weisenburger DD, Rosenberg PS, Anderson WF (2008) Hairy cell leukaemia: a heterogeneous disease? Br J Hematol 142:45–51
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459
Galani KS, Subramanian PG, Gadage VS, Rahman K, Ashok Kumar MS, Shinde S et al (2012) Clinico-pathological profile of Hairy cell leukemia: critical insights gained at a tertiary care cancer hospital. Indian J Pathol Microbiol 55:61–65
Yuan CM, Yang LJ (2008) Hairy cell leukemia with unusual loss of CD103 in a subset of the neoplastic population: immunophenotypic and cell cycle analysis by flow cytometry. Int J Clin Exp Pathol 1(4):381–386
Chen YH, Tallman MS, Goolsby C, Peterson L (2006) Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 125(2):251–259
Acknowledgements
This study was supported in part by “Intramural Research Grant (No. 71/8-Edu-15/176) to Dr. Shano Naseem, from Postgraduate Institute of Medical Education and Research, Chandigarh, India”.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Naseem, S., Gupta, O., Binota, J. et al. BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system. Mol Biol Rep 47, 4365–4372 (2020). https://doi.org/10.1007/s11033-020-05509-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-020-05509-0